Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7846846 | 0.74 | BRD4 (0.40) | LMNAKDM4EMEN1POLBKMT2A | |
| SCHEMBL23840126 | 0.74 | NOS3 (0.39) | LMNAKDM4EMEN1POLBKMT2A | |
| SCHEMBL9138052 | 0.73 | SLC40A1 (0.49) | LMNAKDM4EMEN1KMT2ASRC | |
| SCHEMBL29697758 | 0.73 | GRIA1 (0.46) | LMNAKDM4EMEN1POLBKMT2A | |
| SCHEMBL858288 | 0.73 | SRC (0.34) | SRC | |
| SCHEMBL19511770 | 0.73 | SRC (0.46) | LMNAKDM4EMEN1KMT2ASRC | |
| SCHEMBL5694803 | 0.71 | LMNA (0.33) | LMNAKDM4EMEN1POLBKMT2A | |
| SCHEMBL2770000 | 0.71 | LMNA (0.33) | LMNAKDM4EMEN1POLBKMT2A | |
| SCHEMBL180561 | 0.69 | HTR1D (0.39) | SRCPARP1 | |
| SCHEMBL2940438 | 0.67 | NOS1 (0.36) | SRCPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926714-A1 | ISOTOPICALLY SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | Nycomed GmbH (DE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007023135-A1 | ISOTOPICALLY SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NYCOMED GMBH (DE) | 2007-03-01 | — | — | WO | disclosed |
| US-20070037840-A1 | Tricyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-02-15 | — | — | US | disclosed |
| EP-1697357-A2 | TRICYCLIC BENZIMIDAZOLES | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058893-A8 | TRICYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2005058893-A1 | TRICYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037840-A1 | Tricyclic benzimidazoles | VIP, GIPR, PGC | LMNA 3684/4885KDM4E 2263/4885MEN1 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.